1. Introduction {#sec1}
===============

Gastrointestinal cancer is one of the major malignant diseases detrimental to health. Esophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC) are the major malignancies of gastrointestinal cancer. EC is the sixth leading cause of cancer-related death worldwide, GC is the third and CRC is the fifth \[[@B1]\]. Although the overall survival (OS) of patients with gastrointestinal cancer has improved due to growing early detection and more widespread implementation of radical surgery, plenty of patients with gastrointestinal cancer continue to be diagnosed at advanced stages and therefore lose the optimal opportunity for radical cure. Therefore, searching for ideal diagnostic and prognostic biomarker is significant to improve the curative effect of gastrointestinal cancer.

Recently, researches on signal transduction pathways have revealed the Hippo-YAP pathway plays a vital part in modulating tissue homeostasis, organ size, and tumor progression. Yes-associated protein 1 (YAP or YAP1), an oncoprotein encoded by the*YAP1* gene located on the human chromosome 11q22, is a transcriptional effector component of the Hippo pathway to regulate cell proliferation and apoptosis \[[@B2]\]. YAP1 was first discovered as an intracellular binding protein and a transcriptional coactivator by Sudol in 1994 \[[@B3]\]. Increasing expression of YAP1 protein was detected in numerous cancers, including esophageal cancer, gastric cancer, and colorectal cancer.

Elevated YAP1 expression was reported to be associated with worse outcomes in gastrointestinal cancer in most studies, but some studies reported the dual functions of YAP1 to promote and inhibit the progression of human malignancies. Suh \[[@B4]\] revealed that YAP1 had a tumor suppressor function in GC. In human colon carcinoma cell line H116, YAP1 interacts with*p73* and increases*p73* transactivation of apoptotic genes \[[@B5]\]. In order to research the relationship between YAP1 protein and prognosis of gastrointestinal cancer, we performed a systematic review and meta-analysis to assess the prognostic implications of elevated YAP1 protein in patients with gastrointestinal cancer.

2. Materials and Methods {#sec2}
========================

2.1. Literature Search {#sec2.1}
----------------------

PubMed, Web of Science, Embase, and Cochrane library databases were searched to retrieve feasible literatures about the theme up to Jul 9, 2018. The key terms used in the search strategy were ("gastrointestinal" or "esophageal" or "gastric" or "stomach" or "colorectal" or "colon") and ("Yes associated protein 1" or "YAP1" or "Yes associated protein" or "YAP"). The eligibility articles were limited to clinical trials. We went over the full text of identified articles. We searched manually to ensure all available studies were included in this meta-analysis. Two investigators (L. Zhang and X. Song) conducted literature collection independently. Different opinions from two investigators were resolved by consultation.

2.2. Study Selection Criteria {#sec2.2}
-----------------------------

Literatures eligible for this meta-analysis were identified according to the following criteria: (1) all patients were diagnosed as EC or GC or CRC by pathological examination; (2) YAP1 protein expression in human tumor tissues was detected; (3) the prognostic value of YAP1 in patients with gastrointestinal cancer was investigated; (4) the hazard ratio (HR) and corresponding 95% confidence interval (CI) could be extracted for overall Survival (OS) or disease-free survival (DFS). The exclusion criteria for articles included (1) non-English language articles; (2) case reports, letters, reviews, conference abstracts, and animal experiments; (3) insufficient data available to estimate outcomes; (4) size of each study arm less than 10 participants; (5) selecting the latest or complete study if one patient cohort was researched in more than one studies.

2.3. Quality Assessment and Data Collection {#sec2.3}
-------------------------------------------

The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of the studies and a score ≥ 6 was regarded as high quality. Two researchers extracted requisite information from all the eligible studies independently, including first author\'s surname, year of publication, nationality, case number, detected method, outcome measure, follow-up months, the cut-off value, HR, and corresponding 95% CI. We selected multivariate result if multivariate and univariate results were both reported in a study.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All meta-analyses were performed with STATA 12.0 Software (Stata Corporation, College Station, TX, USA), and*P* \< 0.05 indicated statistical significance unless otherwise specified. The main outcome was OS or DFS. Pooled HRs with 95% CIs were used to quantitatively determine the association between positive YAP1 expression and clinical prognosis. If the study had reported HR and 95% CI, we extracted them directly. Otherwise, they were determined by the data extracted from Kaplan-Meier survival curves using Engauge Digitizer version 4.1 \[[@B6]\]. We also contacted to the corresponding authors of relevant articles if needed. A pooled HR greater than 1 indicated a shorter survival for the patients with positive YAP1 expression, while HR less than 1 suggested a longer survival. The statistical heterogeneity was measured by the I^2^ statistic and Chi-square test (*P* value) \[[@B7], [@B8]\]. If*P* ≤ 0.05 or*I*^*2*^ ≥ 50%, indicating a problem with statistically heterogeneity, we chose the random-effects model to conduct analyses. In contrast, we used the fixed-effects model. Meta-regression and subgroup analyses were performed to further explore the potential source of heterogeneity. Funnel plot, Egger\'s test, and Begg\'s test were performed to evaluate the publication bias \[[@B9]\].

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

Our search strategy primarily retrieved 531 records. 385 papers were directly excluded by reading the titles and abstracts. After looking through full text of every paper, 97 articles were excluded because they were not related to YAP1 protein or did not study human gastrointestinal cancer. In the remaining 29 papers, 11 papers were excluded for the following reasons: lack some important data (n = 10) or too small sample size (n = 1). Finally, 18 articles published from 2012 to 2018 studied the effect of positive YAP1 expression on patients survival in gastrointestinal cancer were enrolled into this meta-analysis ([Figure 1](#fig1){ref-type="fig"}) \[[@B4], [@B10]--[@B26]\]. The main information of the enrolled studies is showed in [Table 1](#tab1){ref-type="table"}. The 18 studies included 2 studies detecting YAP1 expression in esophageal squamous cell carcinoma (ESCC), 9 in GC, and 7 in CRC. A total of 2941 patients diagnosed with gastrointestinal cancer were included. 11 studies (62.50%) reported on Chinese, 7 studies (31.25%) on Koreans, and only 1 study (6.25%) on Japanese. The YAP1 protein was detected by Immunohistochemistry (IHC) in all the 18 studies, but these studies reported different cut-off values. HRs and 95% CIs for OS and/or DFS were provided directly in 12 studies and estimated from Kaplan-Meier Survival curves in the other 6 studies. According to the NOS, all included articles were of high quality (score≥7), with a mean of 7.67. Thus, all studies were eligible for this meta-analysis.

3.2. Overall Survival {#sec3.2}
---------------------

18 studies provided sufficient information for OS or DFS analysis. The key results of this meta-analysis are shown in [Table 2](#tab2){ref-type="table"}. Because of the heterogeneity between studies in evaluating OS (*I*^*2*^ = 55.1%,*P* = 0.003), a random-effects model was used to pool the HRs. The pooled analysis indicated that higher YAP1 expression was significantly associated with shorter OS in gastrointestinal cancer patients (HR = 1.56; 95% CI: 1.29-1.89;*P* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}). The tumor type subgroup analysis demonstrated negative impact of elevated YAP1 on OS in patients with ESCC (HR = 1.85; 95% CI: 1.25-2.73;*P* = 0.002), GC (HR = 1.41,95% CI: 1.02-1.95;*P* = 0.037), and CRC (pooled HR = 1.75; 95% CI: 1.42-2.15;*P* \< 0.001) ([Figure 3](#fig3){ref-type="fig"}). In regard to country subgroup analysis, higher expression of YAP1 was visibly associated with shorter OS in Japanese patients (pooled HR = 1.76; 95% CI: 1.08-2.88;*P* = 0.024), Chinese patients (pooled HR =1.70; 95% CI: 1.26-2.29;*P* \< 0.001), and Korean patients (pooled HR = 1.41; 95% CI: 1.10-1.80;*P* = 0.007). For OS, pooled HR values \> 1 were still calculated in subgroup meta-analyses stratified by case number, HR obtained method, and analysis type ([Table 2](#tab2){ref-type="table"}).

3.3. Sensitivity Analyses and Publication Bias {#sec3.3}
----------------------------------------------

We used the random-effects model to assess sensitivity analysis by sequential omission of individual studies, and the outcome was unaffected by any single study ([Figure 4](#fig4){ref-type="fig"}). Then we performed a meta-regression to detect the potential causes for the heterogeneity. The results showed no statistically significant impact of country (*P* = 0.639), tumor type (*P* = 0.779), sample size (*P* = 0.405), analysis type (*P* = 0.830), HR obtained method (*P* = 0.830), or cut-off value (*P* = 0.326) on the combined effect size for OS. Funnel plots, Egger\'s test, and Begg\'s test were used to assess the publication bias of all enrolled studies. Funnel plot ([Figure 5](#fig5){ref-type="fig"}) suggested no publication bias existed, and Egger\'s test supported the same result (*P* = 0.37). Thus, the results of this meta-analysis were dependable.

3.4. Disease-Free Survival {#sec3.4}
--------------------------

5 studies enrolled a total of 869 patients from China and Korea, providing suitable information for DFS analyses. Because of obvious statistical heterogeneity (*I*^2^ = 59.9%;*P* = 0.041) ([Table 3](#tab3){ref-type="table"}), a random-effects model was used to calculate the pooled HR. The result revealed no association between higher level of YAP1 and shorter DFS (pooled HR = 1.33; 95% CI = 0.95--1.88;*P* = 0.101). A forest plot of study-specific HRs for DFS is presented in [Figure 6](#fig6){ref-type="fig"}. All the HRs and corresponding 95% CIs are shown in [Table 3](#tab3){ref-type="table"}. Subgroup analysis of cancer type revealed the adverse effect of elevated YAP1 on DFS in patients with ESCC (pooled HR = 1.83; 95% CI = 1.12-3.00;*P* \< 0.001), but there was no correlation between YAP1 expression and DFS in GC or CRC patients. Moreover, the association between YAP1 and DFS was not significant in both Chinese (pooled HR= 1.17, 95% CI = 0.69-1.97) and Korean (pooled HR = 1.35, 95% CI = 0.89-2.06) populations.

4. Discussion {#sec4}
=============

The Hippo signaling pathway was first identified and named by screening for mutant tumor suppressors in flies, and it was revealed that tumor progressed due to increased cell proliferation and decreased cell apoptosis when the components of the Hippo pathway had loss-of-function mutations \[[@B27]\]. The Hippo pathway is strongly participated in several processes of cancer progression. Evidence shows that the Hippo pathway is interconnected with other cancer-relevant pathways, especially the transforming growth factor-*β* (TGF-*β*), G protein-coupled receptors (GPCRs), and WNT pathways \[[@B28]\].

YAP1 and PDZ-binding motif (TAZ) are the downstream proteins in the Hippo pathway. These two proteins are in charge of controlling cell proliferation and have important regulatory effects on stem cell self-renewal, tissue regeneration, and organ development. YAP1 contains 488 amino acids and several structural domains \[[@B29]\]. The most crucial domains are a TEA DNA-binding domain and two-WW domain. The former binds to the TEA Domain Transcription factor (TEAD), while the latter binds to a transcriptional coactivator, which in turn binds to the PPxY motif present on transcription factors \[[@B30]\]. TAZ, the YAP1 homologous protein, is identified as a 14-3-3 binding protein. It has similarity structure and biological functions \[[@B31]\]. Normally, phosphorylated YAP/TAZ is accumulated in the cytoplasm, maintaining a highly conservative state and without transcriptional kinase activity. Under pathological conditions, the Hippo pathway which is blocked or inactivated loses of the effect on phosphorylating YAP/TAZ. Then YAP/TAZ is combined with the transcription factor TEAD. The complex transfers to the nucleus and promotes the transcription of corresponding genes, resulting in the imbalance between cell proliferation and apoptosis; eventually these changes lead to cell over proliferation and even cause the tumor occurring \[[@B32], [@B33]\]. Although YAP1 is usually identified as an oncoprotein with functions of enhancing the tumor cells survival, migration, tumor angiogenesis, and chemotherapy resistance, some literature supports the idea that YAP1 functions as a tumor suppressor in cancers, for instance, head and neck cancers (HNC) \[[@B34]\], breast cancer \[[@B35]\], hematological malignancy \[[@B36]\], and CRC \[[@B5]\].

Gastrointestinal cancer is one of the major health care problems in the world. We performed the first meta-analysis to provide strong evidence to reveal the prognostic implications of YAP1 in gastrointestinal cancer. Elevated YAP1 protein expression was obviously correlated with shorter OS in patients with gastrointestinal cancer. In the subsequent subgroup analyses, the adverse prognostic role of elevated YAP1 expression remained stable in different country, sample size, HR obtained method, and analysis type. Nevertheless, the existing evidence from included studies was insufficient to prove a definitive correlation between YAP1 and DFS. Our findings showed YAP1 was not an independent prognostic factor for DFS in gastrointestinal cancer. Nonetheless, because of the significant heterogeneity, the results should be treated with caution. This heterogeneity might be partly due to the variation in patients\' selection among the studies. For instance, the proportion of advanced stage patients was different from study to study. Stratified analyses according to clinicopathological characteristics (such as anatomic site and disease stage) were not performed in this meta-analysis for the limitation of available original studies. The analyses can be conducted in the future to further assess the relationship between YAP1 and DFS in gastrointestinal cancer with more available studies.

Furthermore, previous research shows elevated YAP1 expression is also related with shorter relapse free survival (RFS) in gastrointestinal cancer \[[@B12], [@B21]\]. In addition to YAP1 protein, elevated expression of*YAP1* mRNA may also predict worse prognosis in patients with gastrointestinal cancer \[[@B37]\]. YAP1 also plays a role in early diagnosis of gastrointestinal cancer. Da \[[@B38]\] reported that detecting YAP1 and surviving together might help in early diagnosis of gastric carcinoma.

However, there are some deficiencies for this meta-analysis as well. First, there was a problem of heterogeneity in the overall analysis and in some subgroup analyses. Subgroup analyses revealed that the heterogeneity might be due to the different characteristics of the tumor types. Second, the different cut-off values of YAP1 IHC detection might impact on the precision of the prognostic role of YAP1 in gastrointestinal cancer. In order to establish the most suitable cut-off value, further well-designed studies with larger sample size are imperative to carry out. Third, it might be insufficient to provide support for all ethnic groups because all the studies included were carried out in Asian population.

5. Conclusions {#sec5}
==============

In conclusion, our results suggest that YAP1 protein overexpression correlates with shorter OS in gastrointestinal cancer, especially in Asian patients. Furthermore, YAP1 has been considered to be a promising target for therapy of gastrointestinal cancer. Considering of the deficiencies of the present paper, further well-designed, prospective, and national multicenter, large sample researches are imperative to verify the clinical value of YAP1 in gastrointestinal cancer.
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###### 

Main characteristics of all studies included in the meta-analysis.

  **First author**   **Year**   **Country**   **tumor type**   **Case number**   **Follow-up (months)**   **Detected method**   **Cut-off value**       **Multivariate analysis**   **HRs provided from**   **Outcome measures**   **NOS score**
  ------------------ ---------- ------------- ---------------- ----------------- ------------------------ --------------------- ----------------------- --------------------------- ----------------------- ---------------------- ---------------
  Muramatsu          2011       Japan         ESCC             120               1-103                    IHC                   ≥30% of cells stained   yes                         Report                  OS                     7
  Yeo                2012       Korea         ESCC             142               over60                   IHC                   IRS ≥4                  yes                         Report                  OS/DFS                 7
  Huang              2017       China         GC               120               longest96                IHC                   IRS ≥4                  yes                         Report                  OS                     9
  Hong               2017       Korea         GC               166               0-119                    IHC                   ≥10% of cells stained   no                          SC                      OS/DFS                 8
  Hu                 2014       China         GC               214               longest65                IHC                   IRS ≥4                  yes                         Report                  OS                     8
  Li                 2016       China         GC               161               median34                 IHC                   IRS \>2                 yes                         Report                  OS                     8
  Song               2012       Korea         GC               223               5-75                     IHC                   ≥50% of cells stained   yes                         Report                  OS                     7
  Suh                2015       Korea         GC               116               3-51                     IHC                   ≥10% of cells stained   no                          SC                      OS/DFS                 7
  Sun                2017       China         GC               270               107                      IHC                   ≥10% of cells stained   yes                         Report                  OS                     9
  Zhang              2017       China         GC               178               80                       IHC                   IRS ≥3                  no                          SC                      OS                     8
  Choi               2018       Korea         GC               300               over60                   IHC                   IRS ≥6                  no                          SC                      OS/DFS                 8
  Wang               2013       China         CRC              168               1-56                     IHC                   IRS ≥4                  yes                         Report                  OS                     8
  Wang               2018       China         CRC              172               longest50                IHC                   IRS ≥4                  no                          SC                      OS                     7
  Wu                 2017       China         CRC              85                102 to 2572 days         IHC                   H-score \>150           yes                         Report                  OS                     7
  Kim                2013       Korea         CRC              132               longest125               IHC                   IRS ≥7                  yes                         Report                  OS                     7
  Wang               2013       China         CRC              139               over60                   IHC                   ≥10% of cells stained   yes                         Report                  OS                     8
  Ou                 2017       China         CRC              90                longest60                IHC                   IRS ≥2                  no                          SC                      OS                     7
  Yang               2018       China         CRC              145               longest125               IHC                   IRS ≥2                  yes                         Report                  OS/DFS                 8

ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; CRC: colorectal cancer; IHC: immunohistochemistry; IRS: immunoreactivity score; HR: hazard ratio; SC: survival curve; OS: overall survival; DFS: disease free survival; NOS:Newcastle-Ottawa Scale.

###### 

Pooled HR for OS of patients with high expression of YAP1 according to subgroup analyses.

  Outcome subgroup     No. of patients   No. of studies   Fixed-effects model   Heterogeneity          
  -------------------- ----------------- ---------------- --------------------- --------------- ------ -------
  OS                   2941              18               1.56(1.29,1.89)       \<0.001         55.1   0.003
  Tumor type                                                                                            
   ESCC                262               2                1.85(1.25,2.73)       0.002           0      0.748
   GC                  1748              9                1.41(1.02,1.95)       0.037           70     0.001
   CRC                 931               7                1.92(1.32,2.78)       \<0.001         0      0.521
  Contry                                                                                                
   China               1742              11               1.70(1.26,2.29)       \<0.001         67.1   0.001
   Korea               1079              6                1.41(1.10,1.80)       0.007           27.7   0.227
   Japan               120               1                1.76(1.08,2.88)       0.024           \-     \-
  Case number                                                                                           
   \<150               1089              9                1.72(1.27,2.33)       \<0.001         47     0.057
   ≥150                1852              9                1.45 (1.13,1.86)      0.003           60     0.009
  HR obtained method                                                                                    
   Reported            2085              12               1.61(1.24,2.10)       \<0.001         64.2   0.001
   SC                  856               6                1.58(1.25,2.00)       \<0.001         21.1   0.275
  Analysis type                                                                                         
   Multivariate        2085              12               1.61(1.24,2.10)       \<0.001         64.2   0.001
   Univariate          856               6                1.58(1.25,2.00)       \<0.001         21.1   0.275

OS: overall survival; ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; CRC: colorectal cancer; HR: hazard ratio; CI: confidence interval; SC: survival curve.

###### 

Pooled HR for DFS of patients with high expression of YAP1 according to subgroup analyses.

  Outcome subgroup   No. of patients   No. of studies   Fixed-effects model   Heterogeneity          
  ------------------ ----------------- ---------------- --------------------- --------------- ------ -------
  DFS                869               5                1.33(0.95,1.88)       \<0.001         59.9   0.041
  Tumor type                                                                                          
   ESCC              142               1                1.83(1.12,3.00)       0.016           \-     \-
   GC                582               3                1.18(0.66,2.11)       0.584           76.4   0.014
   CRC               145               1                1.17(0.69,1.88)       0.556           \-     \-
  Contry                                                                                              
   China             145               1                1.35(0.89,2.06)       0.556           \-     \-
   Korea             724               4                1.17(0.95,1.88)       0.159           67.4   0.027

DFS: disease-free survival; ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; CRC: colorectal cancer; HR: hazard ratio; CI: confidence interval.
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